A detailed history of Engineers Gate Manager LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 46,896 shares of CPRX stock, worth $1.01 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
46,896
Previous 86,548 45.82%
Holding current value
$1.01 Million
Previous $1.34 Million 30.45%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.19 - $21.35 $602,313 - $846,570
-39,652 Reduced 45.82%
46,896 $932,000
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $886,774 - $1.02 Million
-60,407 Reduced 41.11%
86,548 $1.34 Million
Q1 2024

May 15, 2024

BUY
$13.18 - $17.11 $1.94 Million - $2.51 Million
146,955 New
146,955 $2.34 Million
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $1.2 Million - $1.54 Million
102,731 New
102,731 $1.2 Million
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $372,997 - $547,531
26,011 New
26,011 $431,000
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $155,072 - $340,896
-21,965 Reduced 36.46%
38,274 $491,000
Q2 2022

Aug 15, 2022

BUY
$6.23 - $8.57 $117,086 - $161,064
18,794 Added 45.35%
60,239 $422,000
Q1 2022

May 16, 2022

BUY
$5.31 - $8.31 $220,072 - $344,407
41,445 New
41,445 $344,000
Q4 2021

Feb 14, 2022

SELL
$5.21 - $7.45 $80,207 - $114,692
-15,395 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$4.85 - $6.04 $148,933 - $185,476
-30,708 Reduced 66.61%
15,395 $82,000
Q2 2021

Aug 16, 2021

SELL
$4.29 - $6.05 $42,741 - $60,276
-9,963 Reduced 17.77%
46,103 $265,000
Q1 2021

May 17, 2021

BUY
$3.45 - $4.69 $147,901 - $201,060
42,870 Added 324.87%
56,066 $258,000
Q4 2020

Feb 16, 2021

SELL
$2.97 - $3.83 $618,241 - $797,260
-208,162 Reduced 94.04%
13,196 $44,000
Q3 2020

Nov 16, 2020

BUY
$2.97 - $5.08 $657,433 - $1.12 Million
221,358 New
221,358 $657,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.22B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.